FEMALES
The mean age of the 126 female patients finally included in the trial was 20 years (range 15 to 46).
In all, 200 females were treated with spectinomycin during the trial period. Most attended the clinic as notified source contacts or secondary contacts of men proven to have gonorrhoea.
The great majority were asymptomatic and most were without definite clinical signs of infection.
After being interviewed each patient was examined and had specimens taken from both urethra and endocervix with buffered cotton-wool swabs. Smears were made and the swabs placed in Stuart's transport medium for culture on both blood agar and Amies' plates.
All cases included in the trial grew gonococci from the cervix and/or urethra confirmed by oxidase and sugar reactions.
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Among those treated on this epidemiological basis there were 64 from whom gonococci were not isolated so they were not included in the trial. Most of these 64 had follow-up tests, all of which proved negative.
Those without a definite history of gonorrhoea contact were treated only after bacteriological proof of their infection.
Follow-up was by emination and repetition of the initial tests at 2 to 5 days, again at 7 to 10 days, and, where possible, at 14 to 21 days after treatment.
Results (Table I In each case two smears were made from the urethral discharge, one of which was sent to the laboratory together with a buffered cotton-wool swab of the discharge placed in Stuart's transport medium. The other smear was examined in the clinic after methylene blue staining. Where intracellular diplococci were present, a diagnosis of gonorrhoea was presumed. The patient was then given a single intramuscular dose of 2 g. spectinomycin.
In each such case laboratory examination of a Gramstained smear confirmed the finding of presumptive gonococci and, in all but two cases their presence was confirmed by positive culture.
Results (Table II) Of the 99 males treated, 88 returned 1 to 4, mostly 2, days later for the first follow-up, which consisted of examination and the collection of scrapings with a heavy nichrome loop inserted 2 to 3 cm. into the urethra. These were immediately inoculated on to both Amies' and blood agar plates, placed in candle extinction jars and quickly transferred to the laboratory incubator. All proved negative.
76 patients attended mostly 7 to 10 days after treatment for further examination and urethral scrapings. All proved negative on culture.
54 attended from 2 to 5 weeks after treatment for at least one further examination at which smears and cultures were made of any obvious discharge; where there was no discharge, a two-glass urine test was made. Any urine specimen containing threads or other debris was sent for microscopy and culture. The results of several published trials of spectinomycin hydrochloride are summarzed in Table III and although all the trials are not strictly comparable they show fairly consistently that this antibiotic is an effective one-dose treatment for uncomplicated gonorrhoea. There are considerable differences in follow-up and in criteria for distinguishing between re-infections and treatment failures. Antibiotic sensitivity tests have not been reported in all trials and without them comparison between trials from different places is not strictly valid.
Even with these reservations, however, the results of the current trial have confirmed the efficacy of spectinomycin.
Gonorrhoea treatment trials are beset with inherent difficulties, not the least of which is the In this series there were post-treatment infections in five males and five females in which differentiation was easy, whereas there were infections in three males and two females in which there remained serious and unresolvable doubts as to their origin.
Had routine antibiotic sensitivity tests been made on all gonococcal isolates in this trial, apart from aiding comparability of results as mentioned above, there may have been some objective evidence of re-infection had any case shown marked sensitivity differences between pre-and post-treatment isolates.
In numerous reported gonorrhoea treatment trials, especially in males, it has been assumed that infections noted later than 2 weeks (in some cases, even 1 week) after treatment were re-infections. Such an assumption, however convenient, appears to be too simple. In this trial the three possible treatment failures in males were all found only in the third test carried out from 2 to 5 weeks after treatment.
Spectinomycin usually takes effect very rapidly. In eleven men who returned almost exactly 24 hours after treatment, either very little or no discharge was evident and many of those treated remarked on the apparent overnight disappearance of the discharge. However, similar very rapid clearances are common with adequate penicillin or ampicillin and probenecid treatment.
No side-effects were reported, but about 5 per cent. of both males and females volunteered that they had suffered pain at the injection site for 1 or 2 days.
The doses of spectinomycin used were those the manufacturers recommend. In view of the now common use of the same dose of penicillin or ampicillin for both males and females with gonorrhoea, the need for the larger dose of spectinomycin in females is doubtful and could well be further investigated. In one published trial Spectinomycin is an important addition to gonorrhoea therapy but should be reserved for penicillin sensitive patients and penicillin insensitive infections.
